Start Your Search
Martin NA Frueh
ES09 - How I Do It - Real World Issues in the Diagnosis and Treatment of Metastatic NSCLC (ID 12)
- Event: WCLC 2019
- Type: Educational Session
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Now Available
- Moderators:Margarida Dias, David Dawe, Carlos Cabrera
- Coordinates: 9/08/2019, 13:30 - 15:00, Tokyo (1982)
ES09.03 - How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost (Now Available) (ID 3201)
13:30 - 15:00 | Presenting Author(s): Martin NA Frueh
Chemotherapy alone has been the accepted standard treatment for patients with stage IV non-small cell lung cancer (NSCLC) for more than two decades based on trials demonstrating a survival benefit and improved quality of life. In the first line setting, the addition of the anti-VEGF antibody (AB) bevacizumab and anti-EGFR ABs cetuximab and necitumumab resulted in modest improvement of survival. Recently, immune-checkpoint inhibitors (ICI) have revolutionized systemic treatment approaches of patients with EGFR/ALK wild type NSCLC in the first and further line setting, mainly due to their ability to achieve long-term tumor control in a subset of patients. Although a considerable proportion of patients doesn`t respond to ICI, immunotherapy is now widely used in combination with chemotherapy as first line treatment in an increasing number of patients as a result of the absence of a reliable predictive biomarker. This situation leaves physicians in the dilemma of balancing the benefit of potential long term disease control in a limited number of patients with the harms which include not only toxicities but also costs. The implementation of novel ICI treatment options in the first line treatment of metastatic NSCLC into current clinical practise will be discussed.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.